Form 4: Director Deborah Autor Exercises Amneal RSUs

Director Deborah M. Autor acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Summary

• Director Deborah M. Autor exercised 34,819 restricted stock units (RSUs) on May 7, 2026.
• The RSUs converted into Class A Common Stock on a one-for-one basis.
• Following the transaction, the director holds 128,479 shares of Class A Common Stock.
• The director was also granted 19,824 new RSUs on May 6, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard equity compensation and director ownership maintenance rather than a strategic shift or market-moving event.

Positives

• Director maintains a significant equity stake of 128,479 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Future vesting of the newly granted 19,824 RSUs is subject to specific time-based conditions.

Future Outlook

The newly granted 19,824 RSUs are scheduled to vest on the later of the day preceding the first annual meeting of stockholders following the grant date or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that routine RSU vesting and equity grants for board members are standard corporate governance practices in the pharmaceutical sector, intended to incentivize long-term director retention and alignment with shareholder value.

Comparison to Industry Standards

• The transaction follows standard equity compensation structures typical for mid-cap pharmaceutical companies.
• Director ownership levels are consistent with industry benchmarks for independent board members.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Vesting of the 19,824 RSUs granted on May 6, 2026, subject to meeting the defined conditions.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Insider Trading, Form 4, Restricted Stock Units, Director Ownership